EA030622B1 - Способ прогнозирования восстановления функции почек - Google Patents

Info

Publication number

EA030622B1

EA030622B1 EA201390439A EA201390439A EA030622B1 EA 030622 B1 EA030622 B1 EA 030622B1 EA 201390439 A EA201390439 A EA 201390439A EA 201390439 A EA201390439 A EA 201390439A EA 030622 B1 EA030622 B1 EA 030622B1

Authority

EA

Eurasian Patent Office

Prior art keywords

kidney

renal

antibody

damage

antibodies

Prior art date

2010-09-24

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 78
• 230000003907 kidney function Effects 0.000 title abstract description 103
• 238000011084 recovery Methods 0.000 title abstract description 46
• 239000000090 biomarker Substances 0.000 claims abstract description 133
• 229920002674 hyaluronan Polymers 0.000 claims abstract description 126
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 107
• 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 105
• 210000003734 kidney Anatomy 0.000 claims description 149
• 230000006378 damage Effects 0.000 claims description 138
• 210000002700 urine Anatomy 0.000 claims description 80
• 238000012360 testing method Methods 0.000 claims description 74
• 239000000523 sample Substances 0.000 claims description 54
• 238000000502 dialysis Methods 0.000 claims description 48
• 238000004458 analytical method Methods 0.000 claims description 45
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
• 230000035945 sensitivity Effects 0.000 claims description 30
• 229920001184 polypeptide Polymers 0.000 claims description 28
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
• 239000003550 marker Substances 0.000 claims description 27
• 230000027455 binding Effects 0.000 claims description 24
• 108090000623 proteins and genes Proteins 0.000 claims description 22
• 102000004169 proteins and genes Human genes 0.000 claims description 21
• 239000007790 solid phase Substances 0.000 claims description 21
• 238000011161 development Methods 0.000 claims description 18
• 239000013060 biological fluid Substances 0.000 claims description 16
• 239000000758 substrate Substances 0.000 claims description 16
• 239000007787 solid Substances 0.000 claims description 15
• 230000002035 prolonged effect Effects 0.000 claims description 14
• 239000012491 analyte Substances 0.000 claims description 11
• 238000003018 immunoassay Methods 0.000 claims description 10
• 238000004445 quantitative analysis Methods 0.000 claims description 9
• 102000004190 Enzymes Human genes 0.000 claims description 8
• 108090000790 Enzymes Proteins 0.000 claims description 8
• 239000003153 chemical reaction reagent Substances 0.000 claims description 7
• 238000012216 screening Methods 0.000 claims description 7
• 238000003556 assay Methods 0.000 claims description 6
• 238000006243 chemical reaction Methods 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 101150052265 NLRP6 gene Proteins 0.000 claims description 5
• 239000002245 particle Substances 0.000 claims description 5
• 239000012472 biological sample Substances 0.000 claims description 4
• 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
• 230000008901 benefit Effects 0.000 claims description 3
• 239000000463 material Substances 0.000 claims description 3
• 238000012875 competitive assay Methods 0.000 claims description 2
• 238000013461 design Methods 0.000 claims description 2
• 238000009007 Diagnostic Kit Methods 0.000 claims 2
• 101001035951 Homo sapiens Hyaluronan-binding protein 2 Proteins 0.000 claims 1
• 102100039238 Hyaluronan-binding protein 2 Human genes 0.000 claims 1
• 230000003100 immobilizing effect Effects 0.000 claims 1
• 239000005022 packaging material Substances 0.000 claims 1
• 208000033626 Renal failure acute Diseases 0.000 abstract description 33
• 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 abstract description 33
• 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 abstract description 33
• 201000011040 acute kidney failure Diseases 0.000 abstract description 33
• 208000009304 Acute Kidney Injury Diseases 0.000 abstract description 32
• 102000046299 Transforming Growth Factor beta1 Human genes 0.000 abstract description 17
• 101800002279 Transforming growth factor beta-1 Proteins 0.000 abstract description 17
• 229940099456 transforming growth factor beta 1 Drugs 0.000 abstract description 17
• 238000012544 monitoring process Methods 0.000 abstract description 15
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 204
• 229940109239 creatinine Drugs 0.000 description 102
• 210000002966 serum Anatomy 0.000 description 72
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 49
• 208000020832 chronic kidney disease Diseases 0.000 description 43
• 201000010099 disease Diseases 0.000 description 42
• 230000001965 increasing effect Effects 0.000 description 41
• 230000001154 acute effect Effects 0.000 description 39
• 208000012998 acute renal failure Diseases 0.000 description 31
• 238000011282 treatment Methods 0.000 description 30
• 210000004369 blood Anatomy 0.000 description 29
• 239000008280 blood Substances 0.000 description 29
• 230000002485 urinary effect Effects 0.000 description 29
• 208000017169 kidney disease Diseases 0.000 description 26
• 230000007423 decrease Effects 0.000 description 23
• 210000002381 plasma Anatomy 0.000 description 22
• 238000003745 diagnosis Methods 0.000 description 21
• 229940099552 hyaluronan Drugs 0.000 description 21
• KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 21
• 238000013517 stratification Methods 0.000 description 21
• 238000001514 detection method Methods 0.000 description 20
• 230000024924 glomerular filtration Effects 0.000 description 20
• 238000005259 measurement Methods 0.000 description 20
• 208000004880 Polyuria Diseases 0.000 description 19
• 230000035619 diuresis Effects 0.000 description 19
• 206010028980 Neoplasm Diseases 0.000 description 18
• 239000012634 fragment Substances 0.000 description 18
• 235000018102 proteins Nutrition 0.000 description 18
• 230000018109 developmental process Effects 0.000 description 17
• 239000000047 product Substances 0.000 description 17
• 238000012959 renal replacement therapy Methods 0.000 description 17
• 230000008859 change Effects 0.000 description 16
• 108010003272 Hyaluronate lyase Proteins 0.000 description 15
• 102000001974 Hyaluronidases Human genes 0.000 description 15
• 229960002773 hyaluronidase Drugs 0.000 description 15
• 230000007774 longterm Effects 0.000 description 15
• 230000006870 function Effects 0.000 description 13
• 210000001519 tissue Anatomy 0.000 description 13
• 206010061218 Inflammation Diseases 0.000 description 12
• 208000001647 Renal Insufficiency Diseases 0.000 description 12
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 12
• 230000000875 corresponding effect Effects 0.000 description 12
• 230000004054 inflammatory process Effects 0.000 description 12
• 201000006370 kidney failure Diseases 0.000 description 12
• 230000001603 reducing effect Effects 0.000 description 12
• -1 aminoglycosides Chemical compound 0.000 description 11
• 230000034994 death Effects 0.000 description 11
• 231100000517 death Toxicity 0.000 description 11
• 206010005003 Bladder cancer Diseases 0.000 description 10
• 206010040047 Sepsis Diseases 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 210000004027 cell Anatomy 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• 201000000523 end stage renal failure Diseases 0.000 description 10
• 230000006872 improvement Effects 0.000 description 10
• 238000004393 prognosis Methods 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 208000024891 symptom Diseases 0.000 description 10
• 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 9
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
• 208000032843 Hemorrhage Diseases 0.000 description 9
• 206010038540 Renal tubular necrosis Diseases 0.000 description 9
• 230000006907 apoptotic process Effects 0.000 description 9
• 229940088598 enzyme Drugs 0.000 description 9
• 208000014674 injury Diseases 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 102100032912 CD44 antigen Human genes 0.000 description 8
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 8
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 8
• 208000034158 bleeding Diseases 0.000 description 8
• 230000000740 bleeding effect Effects 0.000 description 8
• 201000011510 cancer Diseases 0.000 description 8
• 208000028208 end stage renal disease Diseases 0.000 description 8
• 230000036541 health Effects 0.000 description 8
• 229960000485 methotrexate Drugs 0.000 description 8
• 238000001356 surgical procedure Methods 0.000 description 8
• 108700012411 TNFSF10 Proteins 0.000 description 7
• 102000009618 Transforming Growth Factors Human genes 0.000 description 7
• 108010009583 Transforming Growth Factors Proteins 0.000 description 7
• 239000000427 antigen Substances 0.000 description 7
• 108091007433 antigens Proteins 0.000 description 7
• 102000036639 antigens Human genes 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 7
• 239000002872 contrast media Substances 0.000 description 7
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 230000029142 excretion Effects 0.000 description 7
• 229910001385 heavy metal Inorganic materials 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• 239000002953 phosphate buffered saline Substances 0.000 description 7
• 239000011734 sodium Substances 0.000 description 7
• 210000003462 vein Anatomy 0.000 description 7
• 102000014914 Carrier Proteins Human genes 0.000 description 6
• 206010061818 Disease progression Diseases 0.000 description 6
• 206010018364 Glomerulonephritis Diseases 0.000 description 6
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
• 108091008324 binding proteins Proteins 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 206010012601 diabetes mellitus Diseases 0.000 description 6
• 230000005750 disease progression Effects 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 239000003814 drug Substances 0.000 description 6
• 210000002744 extracellular matrix Anatomy 0.000 description 6
• 239000012530 fluid Substances 0.000 description 6
• 230000000302 ischemic effect Effects 0.000 description 6
• 230000003287 optical effect Effects 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 6
• 231100000614 poison Toxicity 0.000 description 6
• 229910052708 sodium Inorganic materials 0.000 description 6
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
• 229960001052 streptozocin Drugs 0.000 description 6
• 230000004083 survival effect Effects 0.000 description 6
• 239000003440 toxic substance Substances 0.000 description 6
• 210000005239 tubule Anatomy 0.000 description 6
• 239000002699 waste material Substances 0.000 description 6
• 239000004971 Cross linker Substances 0.000 description 5
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
• 206010016654 Fibrosis Diseases 0.000 description 5
• 206010020772 Hypertension Diseases 0.000 description 5
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
• 208000027418 Wounds and injury Diseases 0.000 description 5
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
• 210000000683 abdominal cavity Anatomy 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 201000001531 bladder carcinoma Diseases 0.000 description 5
• 230000017531 blood circulation Effects 0.000 description 5
• 210000004204 blood vessel Anatomy 0.000 description 5
• 229930182912 cyclosporin Natural products 0.000 description 5
• 230000006866 deterioration Effects 0.000 description 5
• 230000001434 glomerular Effects 0.000 description 5
• 238000001631 haemodialysis Methods 0.000 description 5
• 230000000322 hemodialysis Effects 0.000 description 5
• 208000028867 ischemia Diseases 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
• 238000012502 risk assessment Methods 0.000 description 5
• 231100000331 toxic Toxicity 0.000 description 5
• 230000002588 toxic effect Effects 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• 210000003954 umbilical cord Anatomy 0.000 description 5
• 201000005112 urinary bladder cancer Diseases 0.000 description 5
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
• 108010036949 Cyclosporine Proteins 0.000 description 4
• 206010019280 Heart failures Diseases 0.000 description 4
• 102000001554 Hemoglobins Human genes 0.000 description 4
• 108010054147 Hemoglobins Proteins 0.000 description 4
• 102000004889 Interleukin-6 Human genes 0.000 description 4
• 108090001005 Interleukin-6 Proteins 0.000 description 4
• 108010051335 Lipocalin-2 Proteins 0.000 description 4
• 102000013519 Lipocalin-2 Human genes 0.000 description 4
• 102100030856 Myoglobin Human genes 0.000 description 4
• 108010062374 Myoglobin Proteins 0.000 description 4
• 206010030302 Oliguria Diseases 0.000 description 4
• 206010061481 Renal injury Diseases 0.000 description 4
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 208000008383 Wilms tumor Diseases 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 229940126575 aminoglycoside Drugs 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 210000000845 cartilage Anatomy 0.000 description 4
• 229960001265 ciclosporin Drugs 0.000 description 4
• 239000003792 electrolyte Substances 0.000 description 4
• 230000008030 elimination Effects 0.000 description 4
• 238000003379 elimination reaction Methods 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 210000000981 epithelium Anatomy 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 230000004761 fibrosis Effects 0.000 description 4
• 230000014509 gene expression Effects 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 229940100601 interleukin-6 Drugs 0.000 description 4
• 201000006334 interstitial nephritis Diseases 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 210000003296 saliva Anatomy 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 229960001967 tacrolimus Drugs 0.000 description 4
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• 238000011269 treatment regimen Methods 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• 206010002329 Aneurysm Diseases 0.000 description 3
• 201000003126 Anuria Diseases 0.000 description 3
• 206010003226 Arteriovenous fistula Diseases 0.000 description 3
• 208000037157 Azotemia Diseases 0.000 description 3
• 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 3
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
• 108010074051 C-Reactive Protein Proteins 0.000 description 3
• 241000234587 Canna Species 0.000 description 3
• 235000005273 Canna coccinea Nutrition 0.000 description 3
• 208000028399 Critical Illness Diseases 0.000 description 3
• 102000012192 Cystatin C Human genes 0.000 description 3
• 108010061642 Cystatin C Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 229920002683 Glycosaminoglycan Polymers 0.000 description 3
• 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 102000008070 Interferon-gamma Human genes 0.000 description 3
• 108010074328 Interferon-gamma Proteins 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 206010029155 Nephropathy toxic Diseases 0.000 description 3
• 102000004264 Osteopontin Human genes 0.000 description 3
• 108010081689 Osteopontin Proteins 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 206010062237 Renal impairment Diseases 0.000 description 3
• 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 3
• 208000007536 Thrombosis Diseases 0.000 description 3
• BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 210000001367 artery Anatomy 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 238000004364 calculation method Methods 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 239000012141 concentrate Substances 0.000 description 3
• 238000002574 cystoscopy Methods 0.000 description 3
• 238000003066 decision tree Methods 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 229940093476 ethylene glycol Drugs 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 210000002683 foot Anatomy 0.000 description 3
• 229960005102 foscarnet Drugs 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 210000002216 heart Anatomy 0.000 description 3
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
• 229960001101 ifosfamide Drugs 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 238000007477 logistic regression Methods 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 239000000203 mixture Substances 0.000 description 3
• BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 3
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 231100000857 poor renal function Toxicity 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 201000001474 proteinuria Diseases 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000009256 replacement therapy Methods 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 201000002327 urinary tract obstruction Diseases 0.000 description 3
• 230000008673 vomiting Effects 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 101710145634 Antigen 1 Proteins 0.000 description 2
• 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 2
• 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
• 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
• 208000034656 Contusions Diseases 0.000 description 2
• 206010010904 Convulsion Diseases 0.000 description 2
• 108060006698 EGF receptor Proteins 0.000 description 2
• 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
• 206010018366 Glomerulonephritis acute Diseases 0.000 description 2
• 208000031361 Hiccup Diseases 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
• 102000011782 Keratins Human genes 0.000 description 2
• 108010076876 Keratins Proteins 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• 108090000265 Meprin A Proteins 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 208000007101 Muscle Cramp Diseases 0.000 description 2
• 102100036836 Natriuretic peptides B Human genes 0.000 description 2
• 101710187802 Natriuretic peptides B Proteins 0.000 description 2
• 206010028813 Nausea Diseases 0.000 description 2
• 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 2
• 208000036576 Obstructive uropathy Diseases 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 208000031481 Pathologic Constriction Diseases 0.000 description 2
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 208000003251 Pruritus Diseases 0.000 description 2
• 206010037596 Pyelonephritis Diseases 0.000 description 2
• 108090000783 Renin Proteins 0.000 description 2
• 102100028255 Renin Human genes 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• 206010041349 Somnolence Diseases 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 102000014456 Trefoil Factor-3 Human genes 0.000 description 2
• 108010078184 Trefoil Factor-3 Proteins 0.000 description 2
• 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 238000013528 artificial neural network Methods 0.000 description 2
• 238000010876 biochemical test Methods 0.000 description 2
• 239000012620 biological material Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 208000034526 bruise Diseases 0.000 description 2
• 244000309464 bull Species 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 239000007795 chemical reaction product Substances 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 230000001268 conjugating effect Effects 0.000 description 2
• 230000036461 convulsion Effects 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 239000007857 degradation product Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 208000002296 eclampsia Diseases 0.000 description 2
• 230000013020 embryo development Effects 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 230000009483 enzymatic pathway Effects 0.000 description 2
• 108091022862 fatty acid binding Proteins 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 150000004676 glycans Polymers 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 230000005484 gravity Effects 0.000 description 2
• 230000036571 hydration Effects 0.000 description 2
• 238000006703 hydration reaction Methods 0.000 description 2
• 230000037451 immune surveillance Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 208000037806 kidney injury Diseases 0.000 description 2
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 201000005857 malignant hypertension Diseases 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000037353 metabolic pathway Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 230000008693 nausea Effects 0.000 description 2
• 230000003589 nefrotoxic effect Effects 0.000 description 2
• 210000000885 nephron Anatomy 0.000 description 2
• 231100000381 nephrotoxic Toxicity 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 201000011461 pre-eclampsia Diseases 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 210000002254 renal artery Anatomy 0.000 description 2
• 210000005084 renal tissue Anatomy 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000036387 respiratory rate Effects 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
• 230000036262 stenosis Effects 0.000 description 2
• 208000037804 stenosis Diseases 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000002381 testicular Effects 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
• 210000000626 ureter Anatomy 0.000 description 2
• 229940116269 uric acid Drugs 0.000 description 2
• 210000001635 urinary tract Anatomy 0.000 description 2
• 238000009423 ventilation Methods 0.000 description 2
• WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
• AQYNZOSCOWGGTP-UHFFFAOYSA-N 2-pyridin-2-ylsulfanylpyridine Chemical compound C=1C=CC=NC=1SC1=CC=CC=N1 AQYNZOSCOWGGTP-UHFFFAOYSA-N 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• 206010068625 Acquired phimosis Diseases 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• 102000011690 Adiponectin Human genes 0.000 description 1
• 108010076365 Adiponectin Proteins 0.000 description 1
• 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 description 1
• 101710186701 Alpha-1-acid glycoprotein 1 Proteins 0.000 description 1
• 208000024985 Alport syndrome Diseases 0.000 description 1
• 102100022749 Aminopeptidase N Human genes 0.000 description 1
• 206010051810 Angiomyolipoma Diseases 0.000 description 1
• 102400000345 Angiotensin-2 Human genes 0.000 description 1
• 101800000733 Angiotensin-2 Proteins 0.000 description 1
• 208000031295 Animal disease Diseases 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 238000008677 BTA stat Test Methods 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
• 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
• 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
• 102100032752 C-reactive protein Human genes 0.000 description 1
• 108010049990 CD13 Antigens Proteins 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• 108010028310 Calbindin 1 Proteins 0.000 description 1
• 102000016838 Calbindin 1 Human genes 0.000 description 1
• 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
• 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
• 102000003846 Carbonic anhydrases Human genes 0.000 description 1
• 108090000209 Carbonic anhydrases Proteins 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000006017 Cardiac Tamponade Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000052052 Casein Kinase II Human genes 0.000 description 1
• 108010010919 Casein Kinase II Proteins 0.000 description 1
• 108010075016 Ceruloplasmin Proteins 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
• 241000819038 Chichester Species 0.000 description 1
• 206010008635 Cholestasis Diseases 0.000 description 1
• 102000003780 Clusterin Human genes 0.000 description 1
• 108090000197 Clusterin Proteins 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 108010091326 Cryoglobulins Proteins 0.000 description 1
• 108010036941 Cyclosporins Proteins 0.000 description 1
• 102000005889 Cysteine-Rich Protein 61 Human genes 0.000 description 1
• 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 1
• 208000026292 Cystic Kidney disease Diseases 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
• 229940097420 Diuretic Drugs 0.000 description 1
• 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
• 102400000686 Endothelin-1 Human genes 0.000 description 1
• 101800004490 Endothelin-1 Proteins 0.000 description 1
• 101710198774 Envelope protein US9 Proteins 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 206010072063 Exposure to lead Diseases 0.000 description 1
• 102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 1
• 102000008857 Ferritin Human genes 0.000 description 1
• 108050000784 Ferritin Proteins 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• 238000000729 Fisher's exact test Methods 0.000 description 1
• 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
• 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
• 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
• 102000013382 Gelatinases Human genes 0.000 description 1
• 108010026132 Gelatinases Proteins 0.000 description 1
• 206010018092 Generalised oedema Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 102000053187 Glucuronidase Human genes 0.000 description 1
• 108010060309 Glucuronidase Proteins 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 108010073791 Glycine amidinotransferase Proteins 0.000 description 1
• 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
• 108010026027 Hemopexin Proteins 0.000 description 1
• 102000013271 Hemopexin Human genes 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
• 241000709721 Hepatovirus A Species 0.000 description 1
• 102100035833 Histo-blood group ABO system transferase Human genes 0.000 description 1
• 101710142776 Histo-blood group ABO system transferase Proteins 0.000 description 1
• 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
• 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
• 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
• 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
• 101001027663 Homo sapiens Fatty acid-binding protein, heart Proteins 0.000 description 1
• 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
• 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
• 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
• 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108050009363 Hyaluronidases Proteins 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
• 206010021263 IgA nephropathy Diseases 0.000 description 1
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
• 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
• 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
• 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
• 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
• 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
• 102000003816 Interleukin-13 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 102000049772 Interleukin-16 Human genes 0.000 description 1
• 101800003050 Interleukin-16 Proteins 0.000 description 1
• 102000003810 Interleukin-18 Human genes 0.000 description 1
• 108090000171 Interleukin-18 Proteins 0.000 description 1
• 102000004125 Interleukin-1alpha Human genes 0.000 description 1
• 108010082786 Interleukin-1alpha Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000004890 Interleukin-8 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 102000000585 Interleukin-9 Human genes 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 108010013792 Isovaleryl-CoA Dehydrogenase Proteins 0.000 description 1
• 102000001399 Kallikrein Human genes 0.000 description 1
• 108060005987 Kallikrein Proteins 0.000 description 1
• 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
• 108010066302 Keratin-19 Proteins 0.000 description 1
• 208000000913 Kidney Calculi Diseases 0.000 description 1
• 201000003129 Kidney Papillary Necrosis Diseases 0.000 description 1
• 206010023421 Kidney fibrosis Diseases 0.000 description 1
• 206010023424 Kidney infection Diseases 0.000 description 1
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
• 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 238000000585 Mann–Whitney U test Methods 0.000 description 1
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
• 206010027525 Microalbuminuria Diseases 0.000 description 1
• 206010027951 Mood swings Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 101100490443 Mus musculus Acvr1 gene Proteins 0.000 description 1
• 101100338009 Mus musculus Gsta1 gene Proteins 0.000 description 1
• 101100123101 Mus musculus Gsta4 gene Proteins 0.000 description 1
• 108010045503 Myeloma Proteins Proteins 0.000 description 1
• 102000005717 Myeloma Proteins Human genes 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 206010029148 Nephrolithiasis Diseases 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 102000009065 Netrin-1 Human genes 0.000 description 1
• 108010074223 Netrin-1 Proteins 0.000 description 1
• 102000019009 Neural Cell Adhesion Molecule L1 Human genes 0.000 description 1
• 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 206010029719 Nonspecific reaction Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 102000008108 Osteoprotegerin Human genes 0.000 description 1
• 108010035042 Osteoprotegerin Proteins 0.000 description 1
• 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
• 108010016731 PPAR gamma Proteins 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 208000036216 Placenta Previa Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
• 102100038358 Prostate-specific antigen Human genes 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 101710132792 Protein P8 Proteins 0.000 description 1
• 102100032421 Protein S100-A6 Human genes 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 206010037597 Pyelonephritis acute Diseases 0.000 description 1
• 102100034328 Rab GDP dissociation inhibitor beta Human genes 0.000 description 1
• 101710193720 Rab GDP dissociation inhibitor beta Proteins 0.000 description 1
• 101000999374 Rattus norvegicus Interferon-related developmental regulator 1 Proteins 0.000 description 1
• 206010065427 Reflux nephropathy Diseases 0.000 description 1
• 206010038548 Renal vein thrombosis Diseases 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 description 1
• 108091006735 SLC22A2 Proteins 0.000 description 1
• 108091006649 SLC9A3 Proteins 0.000 description 1
• 102100037599 SPARC Human genes 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
• 101150000629 TGFB1 gene Proteins 0.000 description 1
• 208000025371 Taste disease Diseases 0.000 description 1
• 229940121792 Thiazide diuretic Drugs 0.000 description 1
• 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
• 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
• 101100393276 Trypanosoma cruzi GP85 gene Proteins 0.000 description 1
• 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
• 208000004608 Ureteral Obstruction Diseases 0.000 description 1
• 206010065584 Urethral stenosis Diseases 0.000 description 1
• 206010046479 Urethral valves Diseases 0.000 description 1
• 206010067863 Uridrosis Diseases 0.000 description 1
• 102000018614 Uromodulin Human genes 0.000 description 1
• 108010027007 Uromodulin Proteins 0.000 description 1
• 208000032594 Vascular Remodeling Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 206010058990 Venous occlusion Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• ZWIJWDCFGVKPGY-RTRLPJTCSA-N [[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]amino] acetate Chemical compound C(C)(=O)ON[C@H]1C(O)O[C@@H]([C@H]([C@@H]1O)O)CO ZWIJWDCFGVKPGY-RTRLPJTCSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000009692 acute damage Effects 0.000 description 1
• 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 201000001555 acute pyelonephritis Diseases 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000011256 aggressive treatment Methods 0.000 description 1
• 150000001350 alkyl halides Chemical group 0.000 description 1
• OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
• 229960003459 allopurinol Drugs 0.000 description 1
• 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 1
• 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 1
• AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 238000004082 amperometric method Methods 0.000 description 1
• 230000002052 anaphylactic effect Effects 0.000 description 1
• 229940035674 anesthetics Drugs 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 229950006323 angiotensin ii Drugs 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• 210000002565 arteriole Anatomy 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 150000001502 aryl halides Chemical class 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 238000013398 bayesian method Methods 0.000 description 1
• 238000013531 bayesian neural network Methods 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000001851 biosynthetic effect Effects 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 208000027503 bloody stool Diseases 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 230000015916 branching morphogenesis of a tube Effects 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical group C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 238000000546 chi-square test Methods 0.000 description 1
• 230000035606 childbirth Effects 0.000 description 1
• 239000000812 cholinergic antagonist Substances 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 238000007727 cost benefit analysis Methods 0.000 description 1
• CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 230000000254 damaging effect Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 239000012502 diagnostic product Substances 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
• 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 230000001882 diuretic effect Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000002848 electrochemical method Methods 0.000 description 1
• 238000000572 ellipsometry Methods 0.000 description 1
• 230000009462 endogenous apoptosis Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 239000003344 environmental pollutant Substances 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 208000001780 epistaxis Diseases 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 210000003722 extracellular fluid Anatomy 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 239000000446 fuel Substances 0.000 description 1
• 230000009760 functional impairment Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 229960003883 furosemide Drugs 0.000 description 1
• 108010074605 gamma-Globulins Proteins 0.000 description 1
• 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000003193 general anesthetic agent Substances 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 102000034238 globular proteins Human genes 0.000 description 1
• 108091005896 globular proteins Proteins 0.000 description 1
• 210000005086 glomerual capillary Anatomy 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 150000002337 glycosamines Chemical group 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000005802 health problem Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 208000035861 hematochezia Diseases 0.000 description 1
• 208000006750 hematuria Diseases 0.000 description 1
• 108091022907 heme binding Proteins 0.000 description 1
• 102000028546 heme binding Human genes 0.000 description 1
• 238000002615 hemofiltration Methods 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 201000011200 hepatorenal syndrome Diseases 0.000 description 1
• 208000003215 hereditary nephritis Diseases 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 201000005991 hyperphosphatemia Diseases 0.000 description 1
• 150000002463 imidates Chemical class 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 201000008269 immune-complex glomerulonephritis Diseases 0.000 description 1
• 229940027941 immunoglobulin g Drugs 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
• 229960001936 indinavir Drugs 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000005305 interferometry Methods 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• 229940118526 interleukin-9 Drugs 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 230000007803 itching Effects 0.000 description 1
• 238000011862 kidney biopsy Methods 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 208000012866 low blood pressure Diseases 0.000 description 1
• 210000004705 lumbosacral region Anatomy 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000006996 mental state Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 235000019656 metallic taste Nutrition 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 230000027939 micturition Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 210000002161 motor neuron Anatomy 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 238000000491 multivariate analysis Methods 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 210000000651 myofibroblast Anatomy 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 238000012273 nephrostomy Methods 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000007694 nephrotoxicity Effects 0.000 description 1
• 231100000637 nephrotoxin Toxicity 0.000 description 1
• HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 230000003448 neutrophilic effect Effects 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 208000009291 paraphimosis Diseases 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000004963 pathophysiological condition Effects 0.000 description 1
• 230000037368 penetrate the skin Effects 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• WFLQAMUOBIONDG-UHFFFAOYSA-N phenoxyarsonic acid Chemical compound O[As](O)(=O)OC1=CC=CC=C1 WFLQAMUOBIONDG-UHFFFAOYSA-N 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 206010034878 phimosis Diseases 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 231100000719 pollutant Toxicity 0.000 description 1
• 208000030761 polycystic kidney disease Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 150000004804 polysaccharides Polymers 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 210000000512 proximal kidney tubule Anatomy 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000012113 quantitative test Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000011472 radical prostatectomy Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000007829 radioisotope assay Methods 0.000 description 1
• 230000006950 reactive oxygen species formation Effects 0.000 description 1
• 238000002310 reflectometry Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000031337 regulation of inflammatory response Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000008085 renal dysfunction Effects 0.000 description 1
• 201000002793 renal fibrosis Diseases 0.000 description 1
• 210000002796 renal vein Anatomy 0.000 description 1
• 230000036454 renin-angiotensin system Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 108091000053 retinol binding Proteins 0.000 description 1
• 102000029752 retinol binding Human genes 0.000 description 1
• 201000009571 retroperitoneal cancer Diseases 0.000 description 1
• 201000004846 retroperitoneal sarcoma Diseases 0.000 description 1
• 210000000574 retroperitoneal space Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 229940063673 spermidine Drugs 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 210000001258 synovial membrane Anatomy 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 239000003451 thiazide diuretic agent Substances 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 150000003573 thiols Chemical group 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 229960001288 triamterene Drugs 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 208000009852 uremia Diseases 0.000 description 1
• 201000001988 urethral stricture Diseases 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
• 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 210000004127 vitreous body Anatomy 0.000 description 1
• 210000004916 vomit Anatomy 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 150000003952 β-lactams Chemical class 0.000 description 1